Reference
1. McNeill A, Robson D. A man before his time: Russell’s insights into nicotine, smoking, treatment and curbing the smoking problem.Addiction (Abingdon, England). 2018;113(4):759-763.
2. R W. Background smoking cessation rates in England. 2006. http://www.smokinginengland.info/Ref/paper2.
3. Powles J, Day N. Interpreting the global burden of disease.Lancet (London, England). 2002;360(9343):1342-1343.
4. Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. International journal of cancer. 2000;85(4):498-502.
5. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Prognosis of chronic pancreatitis: an international multicenter study. International Pancreatitis Study Group. The American journal of gastroenterology. 1994;89(9):1467-1471.
6. Prabhu A, Obi KO, Rubenstein JH. The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis. The American journal of gastroenterology. 2014;109(6):822-827.
7. Krall EA, Garvey AJ, Garcia RI. Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. 2002;4(1):95-100.
8. Grucza RA, Bierut LJ. Cigarette smoking and the risk for alcohol use disorders among adolescent drinkers. Alcoholism, clinical and experimental research. 2006;30(12):2046-2054.
9. Schorling JB, Gutgesell M, Klas P, Smith D, Keller A. Tobacco, alcohol and other drug use among college students. Journal of substance abuse. 1994;6(1):105-115.
10. Craig TJ, Van Natta PA. The association of smoking and drinking habits in a community sample. Journal of studies on alcohol.1977;38(7):1434-1439.
11. Dawson DA. Drinking as a risk factor for sustained smoking.Drug and alcohol dependence. 2000;59(3):235-249.
12. Weitzman ER, Chen YY. The co-occurrence of smoking and drinking among young adults in college: national survey results from the United States. Drug and alcohol dependence. 2005;80(3):377-386.
13. Kahler CW, Spillane NS, Metrik J. Alcohol use and initial smoking lapses among heavy drinkers in smoking cessation treatment.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. 2010;12(7):781-785.
14. Elfghi M, Jordan F, Sultan S, Tawfick W. Study within a trial protocol: Same-day consent vs. delayed consent in a randomized trial.Journal of evidence-based medicine. 2020;13(3):246-248.
15. Xu C, Thabane L, Liu T, Borhan A, Sun X. Flexible piecewise linear model for investigating dose-response relationship in meta-analysis: Methodology, examples, and comparison. Journal of evidence-based medicine. 2019;12(1):63-68.
16. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.BMJ (Clinical research ed). 2011;343:d5928.
17. Li Y, Cao L, Zhang Z, et al. Reporting and methodological quality of COVID-19 systematic reviews needs to be improved: an evidence mapping.Journal of clinical epidemiology. 2021;135:17-28.
18. Pan B, Ge L, Xun YQ, et al. Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. The international journal of behavioral nutrition and physical activity. 2018;15(1):72.
19. Statacorp N, Statacorp L, Statacorp S, Statacorp L. Stata Statistical Software: Release 13. 2013.
20. Grant RL. The uptake of Bayesian methods in biomedical meta-analyses: A scoping review (2005-2016). Journal of evidence-based medicine. 2019;12(1):69-75.
21. Bold KW, Zweben A, Fucito LM, et al. Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking. Alcoholism, clinical and experimental research. 2019;43(5):937-944.
22. Hurt RT, Ebbert JO, Croghan IT, Schroeder DR, Hurt RD, Hays JT. Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: A randomized controlled trial. Drug and alcohol dependence. 2018;184:12-17.
23. Zawertailo L, Ivanova A, Ng G, Le Foll B, Selby P. Safety and Efficacy of Varenicline for Smoking Cessation in Alcohol-Dependent Smokers in Concurrent Treatment for Alcohol Use Disorder: A Pilot, Randomized Placebo-Controlled Trial. Journal of clinical psychopharmacology. 2020;40(2):130-136.
24. Kahler CW, Cioe PA, Tzilos GK, et al. A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment. Alcoholism, clinical and experimental research. 2017;41(6):1201-1211.
25. Leggio L, Zywiak WH, Edwards SM, Tidey JW, Swift RM, Kenna GA. A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology.2015;232(1):233-243.
26. O’Malley SS, Zweben A, Fucito LM, et al. Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial. JAMA psychiatry.2018;75(2):129-138.
27. Anthenelli RM, Heffner JL, Wong E, et al. A Randomized Trial Evaluating Whether Topiramate Aids Smoking Cessation and Prevents Alcohol Relapse in Recovering Alcohol-Dependent Men. Alcoholism, clinical and experimental research. 2017;41(1):197-206.
28. Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Archives of internal medicine. 2005;165(14):1600-1605.
29. O’Malley SS, Krishnan-Sarin S, McKee SA, et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. The international journal of neuropsychopharmacology. 2009;12(5):589-597.
30. Kalman D, Herz L, Monti P, et al. Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study. Drug and alcohol dependence. 2011;118(2-3):111-118.
31. Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O’Malley SS. A preliminary investigation of varenicline for heavy drinking smokers.Psychopharmacology. 2011;215(4):655-663.
32. Grant KM, Kelley SS, Smith LM, Agrawal S, Meyer JR, Romberger DJ. Bupropion and nicotine patch as smoking cessation aids in alcoholics.Alcohol (Fayetteville, NY). 2007;41(5):381-391.
33. King A, Cao D, Vanier C, Wilcox T. Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study.Alcoholism, clinical and experimental research.2009;33(6):1044-1050.
34. Fridberg DJ, Cao D, Grant JE, King AC. Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking. Alcoholism, clinical and experimental research. 2014;38(10):2622-2629.
35. Hays JT, Hurt RD, Decker PA, Croghan IT, Offord KP, Patten CA. A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. 2009;11(7):859-867.
36. Kishi T, Iwata N. Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. European archives of psychiatry and clinical neuroscience. 2015;265(3):259-268.
37. Wu Q, Gilbody S, Peckham E, Brabyn S, Parrott S. Varenicline for smoking cessation and reduction in people with severe mental illnesses: systematic review and meta-analysis. Addiction (Abingdon, England). 2016;111(9):1554-1567.
38. Yan P, Yao L, Li H, et al. The methodological quality of robotic surgical meta-analyses needed to be improved: a cross-sectional study.Journal of clinical epidemiology. 2019;109:20-29.